

ZYTIGA® (abiraterone acetate) ZYTIGA - Repackaging Stability

SUMMARY

- The company cannot recommend any practices, procedures, or storage conditions that deviate from product labeling. Stability is not guaranteed for ZYTIGA when stored outside of its original packaging. Defer to your institutional/local guidelines for guidance on repackaging pharmaceutical products.
- Based on its mechanism of action, ZYTIGA may harm a developing fetus. Women who are pregnant or women who may be pregnant should not handle ZYTIGA 250 mg uncoated tablets or other ZYTIGA tablets if broken, crushed, or damaged without protection, e.g., gloves.¹

PRODUCT LABELING

Please refer to the following section of the enclosed ZYTIGA® full Prescribing Information that is relevant to your inquiry: HOW SUPPLIED/STORAGE AND HANDLING.

REFERENCE

1. ZYTIGA (abiraterone acetate) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc; https://imedicalknowledge.veevavault.com/ui/approved_viewer?token=7994-ecaf8e16-61b7-48c6-a6ad-2594b810a4af.